přejít na obsah
Resistance to immunotherapeutic antibodies in cancer : strategies to overcome resistance Náhled dokumentu
ZavřítNáhled dokumentu
Probíhá kontrola...

Resistance to immunotherapeutic antibodies in cancer : strategies to overcome resistance

Autor Benjamin Bonavida
Vydavatel: New York, NY : Springer, 2013.
Edice: Resistance to targeted anti-cancer therapeutics, v.2
Vydání/formát:   e-kniha : Document : EnglishZobrazit všechny vydání a formáty
Databáze:WorldCat
Shrnutí:
The current application of antibody-meditated targeted therapy against cancer has resulted in significant objective clinical responses, prolongation of survival and even cures. More than 20 mAbs have been approved for human use targeting a range of different cancers. However, a major drawback of mAb therapeutics is that a subset of patients does not initially respond and another initially responding subset develops  Přečíst více...
Hodnocení:

(ještě nehodnoceno) 0 zobrazit recenze - Buďte první.

Předmětová hesla:
Více podobných

 

Najít online exemplář

Odkazy na tento dokument

Vyhledat exemplář v knihovně

&AllPage.SpinnerRetrieving; Vyhledávání knihoven, které vlastní tento dokument...

Detaily

Žánr/forma: Electronic books
Typ materiálu: Document, Internetový zdroj
Typ dokumentu: Internet Resource, Computer File
Všichni autoři/tvůrci: Benjamin Bonavida
ISBN: 9781461476542 1461476542
OCLC číslo: 857224719
Poznámky: Includes index.
Popis: 1 online resource (xiii, 202 pages) : illustrations.
Obsahy: Resistance to Anticancer Antibodies: From Mechanisms to Solutions / Lina Reslan, Charles Dumontet --
Tumor Antigen-Specific Monoclonal Antibody-Based Immunotherapy, Cancer Initiating Cells and Disease Recurrence / Yangyang Wang, Francesco Sabbatino, Ling Yu --
Overcoming Resistance to Therapeutic Antibodies by Targeting Fc Receptors / Emily L. Williams, Sean H. Lim --
Understanding the Mechanisms of Resistance to Rituximab: Paving the Road for the Development of Therapeutic Strategies to Overcome Rituximab-Resistance / Francisco J. Hernandez-Ilizaliturri --
Tumor Resistance to Antibody-Mediated Immunotherapy and Reversal of Resistance: Rituximab as Prototype / Benjamin Bonavida --
Resistance to the Anti-EGFR Therapy, Beyond KRAS, in Patients with Metastatic Colorectal Cancer / Zacharenia Saridaki, John Souglakos --
Overcoming Resistance of Melanoma to Immunotherapy with Monoclonal Antibodies Against Checkpoints Inhibitors / Peter Hersey, Stuart Gallagher --
Strategies to Overcome TRAIL Resistance in Cancer / Simone Fulda --
Unnatural Amino Acid Antibody Conjugates as Next Generation Biologics / Vaughn Smider --
Antibody-Drug Conjugates: Can Coupling Cytotoxicity and Specificity Overcome Therapeutic Resistance? / Penelope M. Drake, David Rabuka.
Název edice: Resistance to targeted anti-cancer therapeutics, v.2
Odpovědnost: Benjamin Bonavida, editor.
Více informací:

Anotace:

Resistance to Immunotherapeutic Antibodies in Cancer  Přečíst více...

Recenze

Recenze vložené uživatelem
Nahrávání recenzí GoodReads...
Přebírání recenzí DOGO books...

Štítky

Buďte první.
Potvrdit tento požadavek

Tento dokument jste si již vyžádali. Prosím vyberte Ok pokud chcete přesto v žádance pokračovat.

Propojená data


<http://www.worldcat.org/oclc/857224719>
library:oclcnum"857224719"
library:placeOfPublication
owl:sameAs<info:oclcnum/857224719>
rdf:typeschema:Book
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:bookFormatschema:EBook
schema:contributor
schema:datePublished"2013"
schema:description"The current application of antibody-meditated targeted therapy against cancer has resulted in significant objective clinical responses, prolongation of survival and even cures. More than 20 mAbs have been approved for human use targeting a range of different cancers. However, a major drawback of mAb therapeutics is that a subset of patients does not initially respond and another initially responding subset develops resistance to further treatments. At the present time, there are no effective therapies for these subsets of cancer patients. The analyses of underlying mechanisms responsible for resistance are necessary to develop and generate new targeted therapies that overcome the resistance. Resistance to Immunotherapeutic Antibodies in Cancer: Strategies to Overcome Resistance is a timely volume that deals with various mechanisms of resistance to anti-cancer mAbs therapeutics as well as it deals with novel approaches to overcome resistance. The reviews in this volume are written by highly qualified, established and experienced leaders in the field of resistance to anti-cancer mAbs."
schema:exampleOfWork<http://worldcat.org/entity/work/id/1754943023>
schema:genre"Electronic books."
schema:inLanguage"en"
schema:name"Resistance to immunotherapeutic antibodies in cancer : strategies to overcome resistance"
schema:url<http://lib.myilibrary.com?id=517004>
schema:url
schema:url
schema:url<http://site.ebrary.com/id/10743790>
schema:url<http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=622877>
schema:workExample
schema:workExample

Content-negotiable representations

Zavřít okno

Prosím přihlaste se do WorldCat 

Nemáte účet? Můžete si jednoduše vytvořit bezplatný účet.